Enhancement of lymphangiogenesis by TβR-I inhibitor in a mouse model of chronic peritonitis. Mice were treated with 5% thioglycollate (2 mL) and TβR-I inhibitor (LY364947, 1 mg/kg) 3 times a week for 2 weeks. Their diaphragms were then examined for lymphangiogenesis in plaques. (A) LYVE-1 immunostaining (shown in red) of diaphragms treated without (control, left panels) or with TβR-I inhibitor (right panels). Sections were also stained for Mac1 (green) (bottom panels). Bars represent 50 μm. (B) Quantification of LYVE-1-positive area in plaques of the diaphragms treated without (control) or with TβR-I inhibitor (n = 3 for each group). Error bars represent SE (***P < .001). (C) Expression of VEGF-C in inflammatory macrophages in the presence and absence of TβR-I inhibitor. Inflammatory macrophages were harvested from ascites fluid of mice 4 days after induction of peritonitis by intraperitoneal injection of thioglycollate, seeded at 106, and treated with or without TβR-I inhibitor for 24 hours. Error bars represent SD (*P < .05).
